PE-22-28

Quick Facts

Introduction

PE-22-28 is a short, truncated analogue of spadin, a peptide derived from the propeptide that is cleaved off during the maturation of the sortilin receptor. Spadin attracted research interest as a natural blocker of the TREK-1 potassium channel, a target tied to mood regulation, and PE-22-28 was developed as a minimized, more practical fragment that retains the relevant channel-blocking activity. It sits in the nootropic-peptide landscape alongside mood- and plasticity-focused compounds such as Selank and Semax.

The conceptual appeal of PE-22-28 research is its mechanism. Rather than acting on monoamine transporters in the manner of conventional antidepressants, it is studied as an inhibitor of a specific two-pore-domain (K2P) potassium channel, TREK-1, whose blockade has been associated in preclinical work with a comparatively rapid antidepressant-like onset — a property of considerable interest given the delayed action of classical agents.

This profile covers what PE-22-28 is, its relationship to spadin, its proposed TREK-1 mechanism, the antidepressant-like and neuroplasticity research it appears in, and how it compares with related nootropic peptides. Related entries are catalogued in the peptide database.

What is PE-22-28?

PE-22-28 is a seven-residue fragment of spadin, corresponding to a short active region (residues 22–28) of the sortilin propeptide, often referred to as PE. Spadin itself is a 17-residue peptide; researchers found that much of its TREK-1-blocking activity could be preserved in a shorter sequence, and PE-22-28 was identified as a minimized analogue intended to be more stable and synthetically tractable than the full peptide.

The interest in truncating spadin is practical: a shorter peptide is easier to stabilize against degradation and to deliver. Research on PE-22-28 and related analogues has examined modifications and delivery routes — including intranasal administration — aimed at extending its functional window while retaining the channel-targeting activity that defines the spadin family.

Molecular and structural characteristics

PE-22-28 is a compact peptide whose identity is defined less by an elaborate structure than by its relationship to spadin and its target. As a short fragment it carries the minimal sequence associated with TREK-1 blockade, and research on the spadin family has focused on stabilizing this core so that the channel-targeting activity persists long enough to be studied in vivo.

Mechanism of action

The defining mechanism of PE-22-28 is inhibition of the TREK-1 potassium channel (gene KCNK2), a member of the two-pore-domain (K2P) family that produces background, leak potassium currents. TREK-1 helps set neuronal resting membrane potential and excitability, and it is highly expressed in brain regions involved in mood. Genetic deletion of TREK-1 produces an antidepressant-like phenotype in animal models, which is the foundation for the hypothesis that pharmacological blockade could be beneficial.

By inhibiting TREK-1, PE-22-28 is studied as a way to increase the excitability and firing of serotonergic neurons, enhancing serotonergic neurotransmission through a channel-level mechanism rather than by blocking serotonin reuptake. This is the conceptual contrast with conventional antidepressants: the spadin family acts on the electrical properties of mood-relevant circuits directly.

Downstream of this signaling, preclinical research has associated PE-22-28 and spadin with markers of neuroplasticity, including induction of BDNF and increased synaptogenesis in the hippocampus. These changes are proposed to underlie the durability of the antidepressant-like effects observed in models and connect PE-22-28 mechanistically to the broader plasticity themes shared across the nootropic-peptide class.

• Inhibition of the TREK-1 (KCNK2) two-pore-domain potassium channel.
• Increased excitability of serotonergic neurons.
• Enhanced serotonergic neurotransmission via a channel mechanism.
• Reported induction of BDNF and hippocampal synaptogenesis.
• Associated with a rapid antidepressant-like onset in models.

Antidepressant-like and neuroplasticity research

The endpoint most associated with PE-22-28 is antidepressant-like activity. In rodent behavioral paradigms, spadin and its analogues have been studied for effects consistent with reduced depressive-like behavior, often emphasizing a faster onset than classical agents — a property tied to the channel-level mechanism. PE-22-28 was developed specifically to capture this activity in a shorter, more stable form.

Because the mechanism is linked to BDNF and synaptogenesis, PE-22-28 sits in the same broad research conversation as other nootropic peptides studied for mood and plasticity, including the anxiolytic Selank and the cognition-focused Semax. Its TREK-1 mechanism, however, means researchers treat it as mechanistically distinct from those regulatory peptides.

TREK-1 channel research

PE-22-28 is valued in research partly as a pharmacological tool for probing TREK-1 biology. TREK-1 is implicated not only in mood but in nociception, neuroprotection, and the response to volatile anesthetics, so a peptide that selectively blocks it is of interest for dissecting the channel's many roles. This dual identity — candidate mood-modulator and channel-probe — is characteristic of how the spadin family is positioned in the literature.

Comparison: PE-22-28 vs Selank vs Semax

PE-22-28 is most usefully compared with Selank, a tuftsin-derived peptide studied for anxiolytic endpoints, and with Semax, an ACTH-derived peptide studied for cognition. All three are short peptides investigated for central nervous system effects, but PE-22-28 is distinguished by its specific ion-channel target.

Because their mechanisms differ — channel inhibition versus neurotransmitter and neurotrophic modulation — PE-22-28 and Selank are studied as distinct approaches to mood-related endpoints. Full entries for each are in the peptide database.

Half-life and pharmacokinetic considerations

As a small peptide, PE-22-28 is subject to the rapid enzymatic degradation typical of its class, giving it a short circulating half-life. A central motivation for truncating spadin into this fragment, and for exploring further modifications, is to improve stability and extend the functional window relative to the full parent peptide while preserving TREK-1 activity.

Precise human pharmacokinetic parameters are not established, reflecting the compound's preclinical evidence base. Researchers have studied delivery routes including intranasal administration as a way to favor central exposure, and they treat statements about its duration as derived from animal and in-vitro work rather than from controlled human studies.

Reconstitution and handling considerations

Lyophilized PE-22-28 is reconstituted with sterile or bacteriostatic water, added slowly down the vial wall and swirled gently rather than shaken. The reconstituted solution should be clear; cloudiness or particulates indicate it should be discarded. Because the peptide is studied via intranasal and parenteral routes, concentrations are chosen so that small, reproducible volumes deliver the intended amount.

Working concentrations are selected so research volumes are convenient and reproducible. The reconstitution calculator and reconstitution guide describe the general method.

• Add diluent slowly; swirl gently rather than shaking.
• Confirm the solution is clear before use.
• Protect from light and excess warmth.
• Avoid repeated freeze–thaw cycles of reconstituted material.

Storage considerations

Lyophilized PE-22-28 is most stable frozen at −20 °C, kept dry and away from light. Once reconstituted, it is refrigerated at 2–8 °C and used within a limited window; aliquoting reduces how often a given solution is cycled. Nasal preparations in particular benefit from cold storage and protection from light.

Research limitations

PE-22-28's evidence base is preclinical. Its antidepressant-like and neuroplasticity findings come from cell and animal models, with limited independent replication and no established controlled human research. Reported effects are dose-, model-, and route-dependent, and because TREK-1 has roles beyond mood — in pain, neuroprotection, and anesthesia — the broader consequences of blocking it remain open research questions. It is described here strictly for research reference.

• All notable findings are preclinical.
• Independent replication and human data are lacking.
• TREK-1 has multiple physiological roles beyond mood.
• It is not an approved therapy and is described solely for research reference.

Frequently Asked Questions

Related Research Profiles

References

1. Mazella J, Pétrault O, Lucas G, et al. Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. PLoS Biology. 2010.Source
2. Djillani A, Pietri M, Moreno S, et al. Shortened spadin analogs display better TREK-1 inhibition, in vivo stability and antidepressant activity. Frontiers in Pharmacology. 2017.Source
3. Djillani A, Mazella J, Heurteaux C, Borsotto M. Role of TREK-1 in health and disease, focus on the central nervous system. Frontiers in Pharmacology. 2019.